Published online Dec 28, 2024. doi: 10.3748/wjg.v30.i48.5212
Revised: October 25, 2024
Accepted: November 13, 2024
Published online: December 28, 2024
Processing time: 85 Days and 2.5 Hours
The gut microbiome plays a key role in the pathogenesis and disease activity of inflammatory bowel disease (IBD). While research has focused on the bacterial microbiome, recent studies have shifted towards host genetics and host-fungal interactions. The mycobiota is a vital component of the gastrointestinal microbial community and plays a significant role in immune regulation. Among fungi, Candida species, particularly Candida albicans (C. albicans), have been extensively studied due to their dual role as gut commensals and invasive pathogens. Recent findings indicate that various strains of C. albicans exhibit considerable differences in virulence factors, impacting IBD's pathophysiology. Intestinal fungal dysbiosis and antifungal mucosal immunity may be associated to IBD, especially Crohn's disease (CD). This article discusses intestinal fungal dysbiosis and antifungal immunity in healthy individuals and CD patients. It discusses factors influencing the mycobiome's role in IBD pathogenesis and highlights significant contributions from the scientific community aimed at enhancing understanding of the mycobiome and encouraging further research and targeted intervention studies on specific fungal populations. Our article also provided insights into a recent study by Wu et al in the World Journal of Gastroenterology regarding the role of the gut microbiota in the pathogenesis of CD.
Core Tip: This article investigated the relationship between Candida species and inflammatory bowel disease (IBD), focusing on ulcerative colitis and Crohn's disease. It examined how Candida affects IBD development, gut barrier function, immune response, and microbiota balance. The role of Candida-derived β-glucans in proinflammatory reactions and the potential use of Candida albicans as a disease marker were discussed. New treatment approaches, including antifungal and immunomodulatory strategies, were also covered. This review suggested that an altered number of Candida species can serve as biomarker for disease severity and treatment outcomes, leading to new diagnostic tools and personalized therapy for IBD.